SecBot SecBot
SECBOTREPLAY Home › Report › RIGL

RIGL · Rigel Pharmaceuticals reported Q1 2026 GAAP diluted EPS of $0.44,…

RIGEL PHARMACEUTICALS INC · 8-K filed May 5, 2026 at 16:08 ET

At the news

BEARISHIMPACT 7/10

8-K filed May 5, 2026 at 16:08 ET

Rigel Pharmaceuticals reported Q1 2026 GAAP diluted EPS of $0.44, missing consensus of $0.74 by 40.5%, despite 10% YoY revenue growth to $58.8M. Net income declined 24% YoY to $8.7M, and the company maintained its full-year revenue guidance of $275-290M. The miss was driven by higher R&D and SG&A costs, overshadowing strong product sales growth.

  • Q1 2026 total revenues: $58.8M (up 10% YoY from $53.3M)
  • Net product sales: $54.9M (up 26% YoY)
  • GAAP diluted EPS: $0.44 vs consensus $0.74 (40.5% miss)
  • Net income: $8.7M vs $11.4M in Q1 2025 (down 24%)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access